Optimal use of Vasoactive Agents in Septic Shock

  • J. L. Vincent
Chapter
Part of the Current Concepts in Critical Care book series (CRITICAL CARE)

Abstract

For many years the treatment of septic shock essentially concentrated on the restoration of systemic blood pressure. Metaraminol, mephentermine, noradrenaline, angiotensin and other vasoconstrictors were widely used with rather limited success. More recently, dopamine has become the agent of choice as a vasopressor in the management of circulatory shock. There are several reasons for this. In the first place it combines alpha- and beta-mimetic properties of various strengths according to the dose administered, so that the drug can easily be titrated according to the clinical status of the patient. Secondly, it induces tachyarrhythmias less frequently than other available catecholamines. Finally, it can selectively dilate renal and mesenteric vascular beds when low doses are used.

Keywords

Septic Shock Fluid Administration Adult Respiratory Distress Syndrome Vasoactive Agent Myocardial Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abraham E, Bland RD, Cobo JC, Shoemaker WC (1984) Sequential cardiorespiratory patterns associated with outcome in septic shock. Chest 85:75–80.PubMedCrossRefGoogle Scholar
  2. Azimi G, Vincent JL (1986) Long term survival from septic shock: Is there a typical hemodynamic pattern? Resuscitation 14:245–253.PubMedCrossRefGoogle Scholar
  3. Baumgartner JD, Vaney C, Perret C (1984) An extreme form of hyperdynamic syndrome in septic shock. Intensive Care Med 10:245–249.PubMedCrossRefGoogle Scholar
  4. Bristow MR, Ginsburg R, Minobe W et al. (1982) Decreased catecholamine sensitivity and beta-adrener-gic-receptor density in failing human hearts. N Engl J Med 307:205–211.PubMedCrossRefGoogle Scholar
  5. Chaudry IH (1983) Cellular mechanisms in shock and ischemia and their correction. Am J Physiol 245:R117–R134.PubMedGoogle Scholar
  6. Chernow B, Roth BL (1986) Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock 18:141–155.PubMedGoogle Scholar
  7. Clowes GH, Farrington GH, Zuschneid W, Cossette GR, Saravis C (1970) Circulating factors in the etiology of pulmonary insufficiency and right heart failure accompanying severe sepsis (peritonitis). Ann Surg 171:663–678.PubMedCrossRefGoogle Scholar
  8. Domb M, Vincent JL, Azimi G et al. (1985) Dopamine versus dobutamine in septic shock: relevance to intravenous fluid administration. Crit Care Med 134:316Google Scholar
  9. Domb M, Van Der Linden P, Azimi G et al. (1986) Treatment of septic shock with amrinone: an experimental study. Crit Care Med 14(4):347.CrossRefGoogle Scholar
  10. Ellrodt AG, Riedinger MS, Kimchi A et al. (1985) Left ventricular performance in septic shock: reversible segmental and global abnormalities. Am Heart J 110:402–409.PubMedCrossRefGoogle Scholar
  11. Francis GS, Sharma B, Hodges M (1982) Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J 103:995–1000.PubMedCrossRefGoogle Scholar
  12. Gustafsson D, Lundvall J (1984) B2-adrenergic vascular control in hemorrhage and its influence on cardiac performance. Am J Physiol 246:H351–H359.PubMedGoogle Scholar
  13. Lefer AM (1970) Role of a myocardial depressant factor in the pathogenesis of circulatory shock. Fed Proc 29:1836–1847.PubMedGoogle Scholar
  14. Leier CV, Heben PT, Huss P, Bush CA, Lewis RD (1978) Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cariomyopathic heart failure. Circulation 58:466–475.PubMedGoogle Scholar
  15. McDonough KH, Lang CH, Spitzer JJ (1985) The effect of hyperdynamic sepsis on myocardial performance. Circ Shock 15:247–259.PubMedGoogle Scholar
  16. Molloy WD, Dobson K, Girling L, Greenberg ID, Prewitt RM (1984) Effects of dopamine on cardiopulmonary function and left ventricular volumes in patients with acute respiratory failure. Am Rev Respir Dis 130:396–399.PubMedGoogle Scholar
  17. Parker MM, Shelhamer JH, Bacharach SL et al. (1984) Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483–490.PubMedGoogle Scholar
  18. Parrillo JE (1986) Cardiovascular dysfunction in humans with septic shock. In: Vincent JL (ed) Update in intensive care and emergency medicine, Vol 1. Springer-Verlag, Berlin Heidelberg New York, pp 265–274.Google Scholar
  19. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W (1985) A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 76:1539–1553.PubMedCrossRefGoogle Scholar
  20. Regnier B, Safran D, Carlet J, Teisseire B (1979) Comparative haemodynamic effects of dopamine and dobutamine in septic shock. Intensive Care Med 5:115–120.PubMedCrossRefGoogle Scholar
  21. Schramm M, Thomas G, Towart R, Frankowiak G (1982) Activation of calcium channels by novel dihydropyridines: a new mechanism for positive inotropic agents. Nature (Lond) 303:535–537.CrossRefGoogle Scholar
  22. Tyden H, Nystrom SO (1983) Dopamine versus dobutamine after open-heart surgery. Acta Anesthesiol Scand 27:193–198.CrossRefGoogle Scholar
  23. Vincent JL, Weil MH, Puri V, Carlson RW (1981) Circulatory shock associated with purulent peritonitis. Am JSurg 142:262–270.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. L. Vincent

There are no affiliations available

Personalised recommendations